Compare Ascendis Pharma A/S (ASND) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Keysight Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Keysight Technologies Inc trades at $322.21 (market cap $55.04B). The key difference: Keysight Technologies Inc is far larger — about 3.1× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | KEYS | |
|---|---|---|
Market Cap | $17.74B | $55.04B |
Sector | Health | Technology |
52-Week High | $277.18 | $373.34 |
52-Week Low | $163.32 | $158.51 |
Enterprise Value | $18.11B | $55.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KEYS trades at $322.05, down 0.04% on the day, with a bearish technical signal despite strong fundamentals. The company reported revenue of $5.38B in 2025 with net income of $850M, and has beaten EPS estimates for three consecutive quarters. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Outlook remains positive with 75% analyst buy ratings and a $390.30 consensus price target, implying 21% upside. Key risks include high valuation multiples and volatile cash flows from significant investing activities. Earnings growth driven by technology demand presents the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
